In the analysis RCC1/SNHG3/SNHG12 as a signature for drug-target response difference and association in pan-cancer, Topotecan, TKI258 and Paclitaxal were found which showed significant differences in different expression levels (Figures 9I,J). The gene discussed is RCC1; the disease is cancer.